KU-55933 (CAS: 587871-26-9)
|
SKU-Pack Size | Availability | Size | Price | |
EBC51008-1ML | In Stock | 1mL(10mM in DMSO) | €89.70 | |
EBC51008-5MG | In Stock | 5mg | €89.70 | |
EBC51008-25MG | In Stock | 25mg | €232.70 | |
EBC51008-50MG | In Stock | 50mg | €349.70 | |
EBC51008-100MG | In Stock | 100mg | €453.70 |
Please Select The Country You Are In To Find Your Local Distributor. |
Cambiotech | Phone£º+44 (0) 188 448801 | |
Lanwades Business Park, | E-mail£ºinfo@cambiotech.com | |
Ireland | Kobenhavn K, Ireland | Web£ºwww.cambiotech.com |
Product Information | |||||||||||||||||||||
Synonym(s) | ATM Kinase Inhibitor | ||||||||||||||||||||
Chemical Name | 2-(4-Morpholinyl)-6-(1-thianthrenyl)-4H-pyran-4-one | ||||||||||||||||||||
Application | ATM Kinase Inhibitor is a cell-permeable, potent, selective and ATP-competitive ATM inhibitor | ||||||||||||||||||||
CAS Number | 587871-26-9 | ||||||||||||||||||||
Purity | ¡Ý99.0% | ||||||||||||||||||||
Molecular Weight | 395.49 | ||||||||||||||||||||
Molecular Formula | C₂₁H₁₇NO₃S₂ | ||||||||||||||||||||
SMILES | C1COCCN1C2=CC(=O)C=C(O2)C3=C4C(=CC=C3)SC5=CC=CC=C5S4 | ||||||||||||||||||||
Target & IC50 | Atm: IC50 = 13 nM mTOR: IC50 = 9.3 ¦ÌM PI3K: IC50 = 16.6 ¦ÌM |
||||||||||||||||||||
Solubility | DMSO: 39.6 mg/mL (100 mM) Ethanol: 19.8 mg/mL (50 mM) |
||||||||||||||||||||
Preparing Stock Solutions |
|
||||||||||||||||||||
Shipping | Gel Pack | ||||||||||||||||||||
Storage | Store at -20¡ã C | ||||||||||||||||||||
Research Use | For Research Use Only. Not Intended for Diagnostic or Therapeutic Use. |
Product Description | |
ATM Kinase Inhibitor (KU 55933) is a cell-permeable, potent, selective and ATP-competitive inhibitor of ATM (Ataxia telangiectasia mutated), a serine/threonine protein kinase, that exhibits an IC50 of 13 nmol/L and a Ki of 2.2 nmol/L. ATM is rapidly and specifically activated in response to DNA double-strand breaks in eukaryotic cells and signals to cell cycle and DNA repair components by phosphorylating downstream targets such as p53, CHK2, NALP2 (NBS1), and BRCA1. |
Specific Protocols | |